The camizestrant approval on 4 September 2026 makes ctDNA-detected progression a US regulatory trigger, months after the EU and UK cleared the drug.
Camizestrant Approval Makes ctDNA Progression a Regulatory Endpoint
read more
Pharma
After EMBRAZE: The Wider Race to Preserve Muscle During GLP-1 Treatment
When results from the phase 2 EMBRAZE trial were published in Nature Medicine in June, apitegromab’s combination with tirzepatide became the most visible evidence yet that pharmacological muscle preservation during GLP-1 treatment might be achievable.¹ But...
The Scale-Up Test
A lab result is only the beginning I have spent close to 20 years developing pharmaceutical, nutraceutical and consumer health products. One lesson has followed me through almost every role: a formula can work beautifully in the laboratory and still become a problem...
Avacopan UK Suspension Follows Retracted Trial Data
The avacopan UK suspension took effect on 1 September 2026. The MHRA stopped supply to new patients and set 1 March 2027 for revoking the UK marketing authorisation, after concluding the pivotal ADVOCATE study can no longer demonstrate efficacy.
Licensing versus Acquisition: How Pharma Chooses
On 26 August 2026, SK Biopharmaceuticals agreed to license an epilepsy platform from Biohaven. Sixteen days earlier, Jazz Pharmaceuticals agreed to buy an epilepsy biotech outright. Same disease area, same month, two opposite structures. The licensing versus...
Lilly Merida Acquisition Bets $2.875bn on Autoantibody Degraders
Eli Lilly has agreed to buy Merida Biosciences for up to $2.875 billion in cash. The Lilly Merida acquisition was announced on 31 August 2026. It hands Lilly a clinical stage platform built to strip single disease causing antibodies out of circulation. The lead...
Oral vs Injectable GLP-1s: The 2026 Weight Loss Drug Shift
The arrival of two approved oral GLP-1 weight loss therapies in the space of four months has fundamentally redrawn the obesity treatment landscape in 2026. For years, the question of whether a daily pill could ever match the efficacy of a weekly injection was largely...
Radiopharmaceuticals: The Cancer Treatment Reshaping Oncology
For decades, oncology ran on a handful of dominant modalities: surgery, chemotherapy, and radiotherapy, later joined by targeted therapies and immunotherapy. Radiopharmaceuticals have now entered that conversation as a serious contender. These drugs combine a...
China Drug Trials Now Outpace the US. Here is What That Means
China has overtaken the United States in the annual number of drug clinical trials. It is a sentence that would have seemed implausible a decade ago. Today, it is simply fact, and the implications for drug development, global pharma strategy, and geopolitical...
Why Biopharma Must Invest in Novel Targets
Drug development continues to concentrate on a small set of well-known targets, creating a crowded landscape where many companies pursue similar pathways. While research into novel mechanisms continues, familiar targets often take priority, reflecting a cautious...
Biologics on the Brink: The Patent Cliff Facing Big Pharma
The global pharmaceutical industry is approaching what many analysts are calling the largest patent cliff biologics in its history. This pharma patent cliff biologics analysts have long anticipated is now arriving in force. Between 2025 and 2030, drugs collectively...
GLP-1 Receptor Agonists Explained: How They Work and Who They’re For
Originally published 15 May 2026. Updated 28 June 2026 to reflect the latest approved indications, pipeline data, and access developments. GLP-1 receptor agonists have moved from specialist diabetes clinics to mainstream medicine with remarkable speed. Once known...
Muscular Dystrophy Has New Treatments. Patients Still Can’t Get Diagnosed
A generation of transformative therapies is arriving for Duchenne muscular dystrophy. Gene therapies have reached the clinic. Oral small molecules targeting the fundamental biology of the disease are entering clinical trials. Newborn screening programmes are being...
CagriSema: The Next Big Obesity Drug? What the Phase 3 Data Shows
The global obesity drug market is in the midst of its most competitive period in a generation. Since the approval of semaglutide as Wegovy and tirzepatide as Zepbound, pharmaceutical companies and investors have been watching closely for the next therapy capable of...
Orforglipron Approved: Inside the Oral GLP-1 Race
The obesity treatment landscape shifted decisively on 1 April 2026, when the US Food and Drug Administration approved Foundayo (orforglipron), an oral once-daily glucagon-like peptide-1 (GLP-1) receptor agonist developed by Eli Lilly. The decision marks the arrival of...
India, Brazil and Southeast Asia: The New Pharma Powerhouses
For most of the twentieth century, the global pharmaceutical industry operated on a straightforward geographic logic. Drugs were discovered and developed in North America and Western Europe, approved by the FDA and EMA, and then exported to the rest of the world. The...
How AI-Driven Research is Reshaping Competitive Intelligence in Pharma
AI developments are happening at breakneck speed, with every sector and industry seeking new opportunities to seize and capitalise upon. AI-driven research is creating a fundamental shift for pharmaceutical competitive intelligence, moving away from a reactive, manual...
A ‘Bariatric-Level’ Obesity Drug Is Coming: Retatrutide and the UK Reality
The pharmaceutical press is having a very loud year. Eli Lilly's investigational triple-agonist retatrutide has produced the kind of phase 2 data that clinicians usually only see in editorials about the future, up to 24.2% mean body-weight reduction at 48 weeks in the...